Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17433539 | 0.74 | BRD4 (0.41) | BRD4BRD2CHRM2CHRM4CHRM5 | |
| SCHEMBL17435214 | 0.73 | BRD4 (0.39) | BRD4BRD2PIK3CD | |
| SCHEMBL16907750 | 0.71 | BRD4 (0.48) | BRD4BRD2CHRM2CHRM4CHRM5 | |
| SCHEMBL167424 | 0.70 | — | — | |
| SCHEMBL19422887 | 0.70 | — | — | |
| SCHEMBL22630165 | 0.70 | — | — | |
| SCHEMBL20436910 | 0.70 | — | — | |
| SCHEMBL1832056 | 0.70 | — | — | |
| SCHEMBL17433530 | 0.68 | BRD4 (0.37) | BRD4BRD2CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL29044201 | 0.68 | BRD4 (0.39) | BRD4BRD2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | SANDOZ AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | CYP51A1, CYP3A5, HCRTR2 | BRD4 1558/4885BRD2 2054/4885PIK3CD 1440/4885 |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | CYP51A1, CYP3A5, HCRTR2 | BRD4 1976/4885BRD2 2345/4885PIK3CD 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.